MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.avsg.2025.09.022

Медицинская библиотека · Annals of vascular surgery · 2025

Drug-Coated Balloon Angioplasty Versus Percutaneous Transluminal Angioplasty for Below-the-Knee Interventions in Chronic Limb-Threatening Ischemia Patients: Systematic Review and Meta-Analysis.

Modi Kush, Joseph Tony, Shah Ruhi, Ranga Raghav, Markel Lawrence

СтатьяСистематический обзорМетаанализПеревод в очереди

Аннотация

BACKGROUND

Drug-coated balloon (DCB) angioplasty is an emerging alternative to percutaneous transluminal angioplasty (PTA) for below-the-knee (BTK) revascularization in patients with chronic limb-threatening ischemia (CLTI). DCBs deliver antiproliferative agents to reduce neointimal hyperplasia, but results are mixed. This review assessed the clinical outcomes of DCB versus PTA in BTK interventions for CLTI.

METHODS

This systematic review and meta-analysis was registered with PROSPERO (CRD420251073999). PubMed and Cochrane Central Register of Controlled Trial were searched for randomized controlled trials and clinical trials comparing DCB and PTA in adult CLTI patients undergoing BTK intervention. Studies until June 2025 were included in the review. Outcomes included clinically driven target lesion revascularization (CD-TLR), major amputation, all-cause mortality, primary patency, and late lumen loss (LLL). Risk of bias (RoB) was assessed using the Cochrane RoB 2 tool, with most studies judged to have low or some concerns but no critical sources of bias. Random-effects model was used to calculate pooled odds ratios (ORs) and standardized mean differences.

RESULTS

Ten studies were included in the review; 7 were eligible for meta-analysis. DCB significantly reduced CD-TLR compared to PTA at 12 months (OR: 0.39; 95% confidence interval [CI]: 0.04-0.73), but not at 5 years. No significant differences were observed in major amputations or all-cause mortality at 12 months or 5 years, though mortality trended lower with DCB in the long term (OR: 0.57; 95% CI: 0.13-1.01). No significant differences between DCB and PTA were found for 6-month primary patency or LLL.

CONCLUSION

DCB reduces early revascularization compared to PTA but shows no significant long-term benefit in amputation or mortality. DCB may be selectively useful in certain patients at high risk of restenosis. Further long-term, risk-stratified studies are needed to optimize DCB use in CLTI management.

Для цитирования: Modi Kush, Joseph Tony, Shah Ruhi, Ranga Raghav, Markel Lawrence. Drug-Coated Balloon Angioplasty Versus Percutaneous Transluminal Angioplasty for Below-the-Knee Interventions in Chronic Limb-Threatening Ischemia Patients: Systematic Review and Meta-Analysis.. Annals of vascular surgery. 2025. DOI: 10.1016/j.avsg.2025.09.022.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.